bpc 157 regulatory news 2025 BIG peptide news: the PCAC meeting is TOMORROW FDA panel to consider easing

Our CRO services include: By combining robust solubility data with physiologically relevant conditions, we help you make informed decisions that accelerate drug development and reduce risk

For a 5mg vial: Add 2.5ml bacteriostatic water Resulting concentration: 2mg/ml (2000mcg/ml) For a 100mcg dose: draw 0.05ml (5 units on a standard insulin syringe) For a 200mcg dose: draw 0.10ml (10 units) For a 10mg vial: Add 3.0ml bacteriostatic water Resulting concentration: 3.33mg/ml (3333mcg/ml) For a 100mcg dose: draw 0.03ml (3 units) For a 200mcg dose: draw 0.06ml (6 units) Alternatively, for easier math with a 5mg vial, you can add 5ml of bacteriostatic water to create a 1mg/ml (1000mcg/ml) concentration

Reconstitute only what you can use within the stability window, or plan to aliquot and freeze the excess immediately

Proper reconstitution, refrigerated storage, and sterile injection practices are essential for safety and efficacy

Drug Testing Considerations: BPC-157 is on the World Anti-Doping Agency (WADA) Prohibited List under S0 (Non-Approved Substances)